UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/506,602	09/10/2004	Shahram Mihan	257502US0PCT	4911	
22850 7590 04/16/2007 OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			EXAMINER		
1940 DUKE STREET ALEXANDRIA, VA 22314		BULLOCK, IN SUK C			
		·	ART UNIT	PAPER NUMBER	
			1764		
		•	NOTIFICATION DATE	DELIVERY MODE	
			04/16/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

. 3		Application No.	Applicant(s)				
	Advisory Action	10/506,602	MIHAN ET AL.	· \			
	Before the Filing of an Appeal Brief	Examiner	Art Unit				
	,	In Suk Bullock	1764 .				
	The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
	REPLY FILED 14 March 2007 FAILS TO PLACE THIS AP						
1. 🛚	☑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:						
a) b)	, , , , , , , , , , , , , , , , , ,						
	no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
NOTICE OF APPEAL 2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS							
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims.							
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): indefiniteness of claim 17.							
6. [timely filed amendme	ent canceling the			
7. 🔀 <u>AFFI</u>			ll be entered and an e	explanation of			
	The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).	d sufficient reasons why the affiday	rit or other evidence is	s necessary and			
9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER							
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
	Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s)					

Continuation of 11. does NOT place the application in condition for allowance because: the arguments are not persuasive.

It is to be noted that the status indentifier for claim 1 is incorrect. The correct status identifier for the claim should be "currently amended." For purpose of appeal, please correct the status identifier.

Applicants argue that "the Examples of the present specification demonstrate that catalysts according to the present invention provide superior results relative to, for example, the catalysts of Maas." Comparative Example 4 which corresponds to Example 21 of Maas, is not deemed to be an objective evidence of the improvement over the catalyst of present claim 1 because Maas teaches various ligands including the claimed ligand. One of ordinary skill in the art could determine the most effective ligand among those disclosed by Maas to achieve desired results.

Regarding Comparative Example 3 which shows criticality of B:Cr ratio of above 2, Mass discloses B:Cr ratio of at least 10 which overlaps with the claimed ratio of at least 5. Therefore, the showing of superior results when B:Cr ratio is 10 over a B:Cr ratio of 2 does not commensurate with the scope of claim.

J. Budoch

Glenn Caldarola Supervisory Patent Examiner Technology Center 1700